Correction: Discovery and clinical introduction of first-in-class imipridone ONC201
Metrics: PDF 1018 views | ?
1 Oncoceutics, Inc., Philadelphia, PA, USA
2 Fox Chase Cancer Center, Philadelphia, PA, USA
3 University of Texas MD Anderson Cancer Center, Houston, TX, USA
4 Weill Cornell Medicine, New York, NY, USA
6 Harvard Medical School, Boston, MA, USA
7 Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
8 Provid Pharmaceuticals, Monmouth Junction, NJ, USA
9 Kuwait University Medical School, Kuwait
10 Karmanos Cancer Institute, Detroit, MI, USA
11 The Children’s Hospital of Philadelphia, Philadelphia, PA, USA
Published: October 12, 2021
Copyright: © 2021 Allen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article has been corrected: The COI statement has been updated. Please see the revised text below:
CONFLICTS OF INTERESTW.S.E-D. is a co-founder and shareholder of Oncoceutics, Inc. W.S.E-D. is fully compliant with institutional disclosure requirements and conflict of interest rules. Dr. Michael Andreeff is also a shareholder of Oncoceutics, Inc. Some of the additional authors are employees or shareholders at Oncoceutics, Inc.
Original article: Oncotarget. 2016; 7:74380–74392. DOI: https://doi.org/10.18632/oncotarget.11814
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.